Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced it has begun testing MB-204 in the Oprm 1 m odel of autism in collaboration with Dr. Julie Le Merrer and Dr. Jer e Becker at the iBrain Institute, Tours, France. The company seen immediate effects of MB-204 after a single dose in mouse models of depression, which gives confidence the drug could offer improvements in these autistic behaviours after a short course therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.155 CAD | 0.00% | +14.81% | +93.75% |
Mar. 26 | Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
Mar. 25 | Marvel Biosciences Announces Positive Interim Results For MB-204 | MT |
1st Jan change | Capi. | |
---|---|---|
+93.75% | 4.49M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- MRVL Stock
- News Marvel Biosciences Corp.
- Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University